Surmodics, Inc. (SRDX)
$
42.98
+0.15 (0.35%)
Key metrics
Financial statements
Free cash flow per share
-0.2483
Market cap
614.5 Million
Price to sales ratio
5.0870
Debt to equity
0.2927
Current ratio
3.9090
Income quality
0.1068
Average inventory
15.9 Million
ROE
-0.1559
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Surmodics, Inc. and its subsidiaries specialize in surface modification technologies for intravascular medical devices as well as chemical components for in vitro diagnostic immunoassay tests and microarrays both in the United States and internationally. The company operates in two primary segments: Medical Device and In Vitro Diagnostics (IVD). The Medical Device segment focuses on surface modification coating technologies to improve access, deliverability, and predictable deployment of medical devices. It also develops drug-delivery coating technologies that facilitate site-specific drug deliveries from the surface of devices targeting coronary, peripheral, neuro-vascular, structural heart markets, and beyond. Furthermore, this segment is involved in the design, development, and manufacturing of interventional medical devices, primarily balloons and catheters, including drug-coated balloons aimed at treating peripheral arterial disease and other applications. The IVD segment specializes in designing, developing, and manufacturing component products and technologies tailored for diagnostic immunoassays, molecular testing, and biomedical research applications, offering a range of products such as protein stabilization reagents, substrates, surface coatings, and antigens. The operating income ratio is -0.04 indicating the company's operational profitability margin. The company incurred an income tax expense of $4,036,000.00 indicating its tax obligations. The company's stock is identified with the symbol 'SRDX' in the market. Additionally, the operating expenses amount to $98,697,000.00 encompassing various operational costs incurred, and the company reported a net loss of -$11,542,000.00 indicating challenges in its operations. The stock is affordable at $32.37 making it suitable for budget-conscious investors. Furthermore, the stock has a low average trading volume of 435,959.00 indicating lower market activity, which may appeal to certain types of investors. With a market capitalization of $614,511,837.00 the company is classified as a small-cap player within the financial markets. Surmodics is a key player in the Medical - Devices industry, significantly contributing to the overall market landscape through its innovative offerings. Additionally, it belongs to the Healthcare sector, driving innovation and growth across its operational dimensions.
What is Surmodics, Inc. (SRDX)'s stock forecast?
Analysts predict Surmodics, Inc. stock to fluctuate between $25.87 (low) and $43.00 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Surmodics, Inc.'s market capitalization?
As of 2025-11-18, Surmodics, Inc.'s market cap is $614,511,837, based on 14,297,623 outstanding shares.
How does Surmodics, Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Surmodics, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Surmodics, Inc. (SRDX) stock?
To buy Surmodics, Inc. (SRDX) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for SRDX. Place an order (Market, Limit, etc.).
What is the best time to invest in Surmodics, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
Has Surmodics, Inc. stock ever split?
Surmodics, Inc.'s last stock split was 2:1 on 2000-12-07.
How did Surmodics, Inc. perform in the last earnings report?
Revenue: $126,078,000 | EPS: -$0.82 | Growth: 645.45%.
Where can I find Surmodics, Inc.'s investor relations reports?
Visit https://www.surmodics.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Surmodics, Inc.?
You can explore historical data from here
What is the all-time high and low for Surmodics, Inc. stock?
All-time high: $62.27 (2021-09-02) | All-time low: $16 (2023-03-20).
What are the key trends affecting Surmodics, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
businesswire.com
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX) (“Surmodics” or the “Company”), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that it expects to close its previously announced acquisition (the “Merger”) of the Company by an affiliate of GTCR LLC (“GTCR”) promptly. In a joint status report filed with the United States District Court for the Northern District of Illinois (the “District Court”), the Feder.
benzinga.com
The United States District Court for the Northern District of Illinois on Tuesday denied a request by the U.S. Federal Trade Commission and certain state regulators to issue a preliminary injunction that would have prevented the proposed acquisition of Surmodics Inc. (NASDAQ:SRDX) by GTCR.
businesswire.com
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX) (“Surmodics” or the “Company”), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that the United States District Court for the Northern District of Illinois (the “District Court”) has denied a request by the U.S. Federal Trade Commission (the “FTC”) and certain state regulators to issue a preliminary injunction that would have prevented the Company and GTCR.
businesswire.com
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that results from an analysis of 160 real-world patients with symptomatic infrainguinal limb ischemia from its PROWL registry study were presented on November 3rd at an industry-sponsored session at the 23rd Annual VIVA Conference in Las Vegas, NV. PROWL national co-principal investigators Dr. Sean Lyden and.
businesswire.com
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that Dr. Sean Lyden, Dr. Joseph Campbell, and Dr. Peter Monteleone, will present and discuss updated safety and performance data from the PROWL registry on 160 patients with symptomatic lower extremity (infrainguinal) vessels treated with the Pounce™ Thrombectomy Platform. The presentation will be held on Mon.
zacks.com
Surmodics delivers third-quarter fiscal 2025 earnings beat with narrower loss, as revenue tops estimates despite lower SurVeil DCB sales.
zacks.com
SurModics (SRDX) came out with quarterly earnings of $0.06 per share, beating the Zacks Consensus Estimate of a loss of $0.21 per share. This compares to a loss of $0.27 per share a year ago.
businesswire.com
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial results for its third quarter ended June 30, 2025, and updated its financial guidance for the fiscal year ending September 30, 2025. Third Quarter Fiscal 2025 Financial Summary Total Revenue of $29.6 million, a decrease of 3% year-over-year Total Revenue excluding SurVeil™ drug-coated balloon (“DCB”).
zacks.com
SurModics (SRDX) reported earnings 30 days ago. What's next for the stock?
See all news
